COVID-19 (Coronavirus) Update

As the level of COVID-19 infections begins to stabilize in our community, we are starting to reschedule appointments, surgeries, and procedures that were delayed during the pandemic. Learn more about how Duke Health is committed to keeping you safe. Visitor restrictions remain in effect. 

Tokalas TK216-01 (Sarcoma) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out how safe and if the study drug (TK216) will work in patients with Ewing Sarcoma.
What is the Condition Being Studied?
Ewing Sarcoma

Who Can Participate in the Study?

Adults with a diagnosis of Ewing Sarcoma whose cancer has gotten worse with standard therapy.

Age Group
Adults, Children

What is Involved?

If you choose to join this study, you will:

Be involved in two parts: Screening and Treatment

During Screening, you will have:
- A physical exam
- A urine sample
- Several imaging tests

During Treatment, you will:
- Be admitted to hospital to get study drug
- Get the study drug (TK216), infused through a central line (an I.V.) until your cancer gets worse, or the study doctor takes you off of the study

Study Details

Full Title
A Phase 1, Dose Escalation Study of Intravenous TK216 in Patients with Relapsed or Refractory Ewing Sarcoma
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00076775
NCT: NCT02657005
Phase I
Contact the Duke Recruitment Innovation Center